These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 26547109)

  • 1. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
    Nakagawa H; Niiro H; Ootaki K;
    J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
    Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
    N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis.
    Umezawa Y; Nakagawa H; Niiro H; Ootaki K;
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1957-1960. PubMed ID: 27358210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
    Seo SJ; Shin BS; Lee JH; Jeong H
    J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
    N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
    J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
    Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
    Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
    JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study.
    Yamaguchi Y; Takatsu N; Ootaki K; Nakagawa H
    J Dermatol; 2020 Jun; 47(6):569-577. PubMed ID: 32275086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
    Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
    Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
    Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
    Cai L; Jiang C; Zhang G; Fang H; Wang J; Li Y; Xu H; Xiao R; Ding Y; Huang K; Zhang C; Zhang L; Chen B; Duan X; Pan W; Han G; Chen R; Liu L; Zhang S; Tao J; Pang X; Yu J; Wang H; Zhao Y; Li C; Kang X; Qin L; Zhu X; Su J; Li S; Yang C; Feng W; Lei T; Jiang S; Fang R; Lin M; Lu Q; Xu C; Wang W; Zhang J
    Br J Dermatol; 2024 Aug; 191(3):336-343. PubMed ID: 38366639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
    Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
    J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1).
    Papp K; Menter A; Leonardi C; Soung J; Weiss S; Pillai R; Jacobson A
    Br J Dermatol; 2020 Dec; 183(6):1037-1048. PubMed ID: 32286683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
    Blair HA
    Drugs; 2018 Mar; 78(4):495-504. PubMed ID: 29516365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.